[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
49. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A: Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res; 2008 Aug 15;68(16):6770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
  • Using gene expression profiling, we found that the CBX7 gene was drastically down-regulated in six thyroid carcinoma cell lines versus control cells.
  • The aims of this study were to determine whether CBX7 is related to the thyroid cancer phenotype and to try to identify new tools for the diagnosis and prognosis of thyroid cancer.
  • We thus evaluated CBX7 expression in various snap-frozen and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by quantitative reverse transcription-PCR and immunohistochemistry, respectively.
  • CBX7 expression progressively decreased with malignancy grade and neoplasia stage.
  • Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas.
  • This finding coincides with results obtained in rat and mouse models of thyroid carcinogenesis.
  • Restoration of CBX7 expression in thyroid cancer cells reduced growth rate, with a retention in the G(1) phase of the cell cycle, suggesting that CBX7 can contribute to the proliferation of the transformed thyroid cells.
  • In conclusion, loss of CBX7 expression correlates with a highly malignant phenotype in thyroid cancer patients.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Repressor Proteins / genetics. Repressor Proteins / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Chromosomes, Human, Pair 22 / genetics. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Mice. Mice, Nude. Polycomb Repressive Complex 1. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701502.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


50. Jakubowski M, Hunt JL: BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol; 2009 Nov;33(11):1590-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns.
  • BACKGROUND: Current literature suggests that up to 60% of papillary carcinomas have mutations in the BRAF gene.
  • However, follicular variant of papillary carcinoma has a much lower frequency of mutation.
  • Tumors with mixed patterns of growth, including distinctive area of follicular and papillary growth, have not been well studied for the presence of the BRAF gene mutation.
  • DESIGN: Cases of papillary carcinoma were identified with well-defined conventional papillary growth pattern, alongside other areas with follicular growth pattern.
  • The tumor stage was obtained, along with demographic information.
  • In comparing the follicular and the papillary growth patterned areas, the BRAF mutation was concordant in all cases.
  • Four cases had an additional separate focus of microscopic papillary carcinomas.
  • CONCLUSIONS: Papillary carcinomas of the thyroid with papillary growth and areas of follicular growth have a high frequency of BRAF mutations.
  • The BRAF mutational profile is identical in the follicular areas and in the conventional papillary growth areas.
  • These molecular data support the common diagnostic decision that a tumor with any amount of conventional papillary growth should be designated as a conventional papillary carcinoma, regardless of the presence of follicular growth pattern areas.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19738460.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


51. Alevizaki M, Papageorgiou G, Rentziou G, Saltiki K, Marafelia P, Loukari E, Koutras DA, Dimopoulos MA: Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental. Thyroid; 2009 Jul;19(7):749-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental.
  • BACKGROUND: New cases of well-differentiated thyroid cancer (DTC) are diagnosed more frequently worldwide.
  • METHODS: During the last 34 years 852 follicular cell-derived DTC cases (83% papillary [PTC], 17% follicular [FTC] carcinoma) presented in the Endocrine Unit of the Department of Clinical Therapeutics in Alexandra Hospital (18.8% men, mean age 42.4 +/- 14.5 years).
  • We recorded the histological type, age at diagnosis, and, in period 3, the type of pre-existing thyroid disease, the stage, and tumor size.
  • [MeSH-major] Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / etiology. Adenocarcinoma, Follicular / pathology. Adult. Female. Goiter, Nodular / complications. Greece / epidemiology. Humans. Incidental Findings. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prevalence

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534620.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Lind P, Kohlfürst S: Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med; 2006 Jul;36(3):194-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
  • Depending on the iodine supply of an area, the incidence of thyroid cancer ranges between 4 and 12/100,000 per year.
  • To detect thyroid cancer in an early stage, the assessment of thyroid nodules includes ultrasonography, ultrasonography-guided fine-needle aspiration biopsy, and conventional scintigraphic methods using (99m)Tc-pertechnetate, (99m)Tc-sestamibi or -tetrofosmin, and (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in selected cases.
  • After treatment of thyroid cancer, a consequent follow-up is necessary over a period of several years.
  • For following up low-risk patients, recombinant thyroid-stimulating hormone-stimulated thyroglobulin and ultrasonography is sufficient in most cases.
  • After total thyroidectomy and radioiodine ablation therapy, thyroid-stimulating hormone-stimulated thyroglobulin should be below the detection limit (eg, <0.5 ng/mL, R: 70-130).
  • In patients with low or dedifferentiated thyroid cancer and after several courses of radioiodine therapy caused by metastatic disease, iodine negative metastases may develop.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Carcinoma, Papillary / radionuclide imaging. Fluorodeoxyglucose F18. Iodine Radioisotopes. Positron-Emission Tomography. Radiopharmaceuticals. Thyroglobulin / blood. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Biomarkers, Tumor / blood. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Lymphatic Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Preoperative Care. Radiometry / methods. Sensitivity and Specificity. Thyroid Nodule / pathology. Thyroid Nodule / radionuclide imaging. Thyroid Nodule / ultrasonography. Thyrotropin. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762610.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 82
  •  go-up   go-down


53. Collini P, Mattavelli F, Spinelli C, Massimino M: Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. Expert Rev Anticancer Ther; 2007 Jan;7(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age.
  • Nonmedullary thyroid carcinomas are rare malignancies in pediatric ages.
  • The vast majority of them are papillary carcinomas with an overall survival of approximately 100%.
  • Their outcome is independent of strong prognostic factors of adults, such as papillary carcinoma histological subtype, invasion into soft tissue of the neck, presence and site of distant metastases, relapse and type of surgery.
  • In most institutions, the therapy of choice for all pediatric thyroid carcinomas is the radical approach, aimed at the eradication at diagnosis of all clinical and subclinical neoplastic foci, both at thyroid, lymph node and distant level.
  • It consists of total thyroidectomy and lymphadenectomy in children with clinically evident lymph-node metastases, followed by radioactive iodine therapy independent of histotype and stage.
  • Recently, owing also to the high sensitivity to hormonal manipulation shown by pediatric papillary carcinomas, a conservative approach has been proposed for selected cases, consisting of the removal of only the grossly detectable disease followed by thyroid-stimulating hormone-suppressive hormonal therapy to control subclinical disease.
  • Today, the existence of two therapeutic approaches, radical versus conservative therapy, should be considered whenever treating a child or adolescent with a nonmedullary thyroid carcinoma.
  • The future tasks include the stratification of thyroid carcinomas into low- and high-risk cases, also including their molecular alterations and the possibility of a molecularly targeted therapy against tyrosine kinases involved in the pathogenesis of thyroid carcinomas.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Follicular / therapy. Child. Humans. Lymph Node Excision

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187518.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


5
Advertisement
4. Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J: Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer; 2006;6:284
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing thyroid cancer incidence in Lithuania in 1978-2003.
  • BACKGROUND: The aim of this paper is to analyze changes in thyroid cancer incidence trends in Lithuania during the period 1978-2003 using joinpoint regression models, with special attention to the period 1993-2003.
  • METHODS: The study was based on all cases of thyroid cancer reported to the Lithuanian Cancer Registry between 1978 and 2003.
  • A change in the trend occurred in which a significant increase changed to a dramatic increase in thyroid cancer incidence rates.
  • Papillary carcinoma and stage I thyroid cancer increases over this period were mainly responsible for the pattern of changes in trend in recent years.
  • CONCLUSION: A moderate increase in thyroid cancer incidence has been observed in Lithuania between the years 1978 and 2000.
  • An accelerated increase in thyroid cancer incidence rates took place in the period 2000-2003.
  • It seems that the increase in thyroid cancer incidence can be attributed mainly to the changes in the management of non palpable thyroid nodules with growing applications of ultrasound-guided fine needle aspiration biopsy in clinical practice.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):137-44 [10710197.001]
  • [Cites] Thyroid. 2001 May;11(5):483-6 [11396706.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1335-9 [11720471.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):51-7 [11815401.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):295-9 [12565980.001]
  • [Cites] J Radiol Prot. 2006 Jun;26(2):127-40 [16738412.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1912-9 [12932671.001]
  • [Cites] Eur J Endocrinol. 2004 Feb;150(2):133-9 [14763910.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1998;106 Suppl 3:S38-44 [9865553.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1056-60 [15650358.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62 [15670190.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):13-7 [12708720.001]
  • (PMID = 17156468.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1764427
  •  go-up   go-down


55. Dralle H, Lorenz K, Machens A: [Surgery of thyroid carcinoma]. Chirurg; 2009 Nov;80(11):1069-82; quiz 1083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of thyroid carcinoma].
  • The 5 main types of thyroid cancer (papillary, PTC, follicular, FTC, poorly differentiated, PDTC undifferentiated, UTC, medullary, MTC) not only differ regarding morphology, pathogenesis, genetics,and pathophysiology (iodine metabolism, thyroglobulin and calcitonin production), but also concerning tumor biology, metastatic behavior (lymphogenous, locally invasive and hematogenous routes) and prognosis.
  • Knowledge of these features is the basis of the surgical concept of one or two-stage thyroidectomy, the exceptions and the concept of locoregional lymph node dissection.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma / surgery. Carcinoma, Medullary / surgery. Carcinoma, Papillary / surgery. Lymph Node Excision / methods. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2006 Dec;140(6):1000-5; discussion 1005-7 [17188149.001]
  • [Cites] Chirurg. 1992 Apr;63(4):282-90 [1597092.001]
  • [Cites] World J Surg. 2007 May;31(5):957-68 [17453286.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1086-8 [19349473.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):167-9 [9641892.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):971-87 [19041826.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1105-13 [16162881.001]
  • [Cites] World J Surg. 2007 Oct;31(10):1960-5 [17665245.001]
  • [Cites] Surgery. 2006 Dec;140(6):953-9 [17188144.001]
  • [Cites] Surg Today. 1994;24(2):112-21 [8054788.001]
  • [Cites] Thyroid. 2009 May;19(5):473-7 [19348582.001]
  • [Cites] Ann Thorac Surg. 2007 Jun;83(6):1952-9 [17532377.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):375-81; discussion 381-4 [17717441.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):171-6 [18982392.001]
  • [Cites] Surgery. 2001 Jan;129(1):23-8 [11150030.001]
  • [Cites] Br J Surg. 2008 May;95(5):586-91 [18300267.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2173-80 [18364376.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):604-10 [17414610.001]
  • [Cites] Ann Thorac Surg. 1992 Jul;54(1):3-9; discussion 9-10 [1610250.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2029-34 [15634717.001]
  • [Cites] Chirurg. 2008 Nov;79(11):1017-28 [18818894.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2070-5 [12727956.001]
  • [Cites] World J Surg. 2004 Apr;28(4):397-401 [14994142.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • [Cites] World J Surg. 2008 Jul;32(7):1313-24 [18449595.001]
  • [Cites] Surgery. 2002 Mar;131(3):249-56 [11894028.001]
  • [Cites] Chirurg. 1996 Aug;67(8):788-806 [8964151.001]
  • [Cites] World J Surg. 2007 Aug;31(8):1672-6 [17571205.001]
  • [Cites] Surgery. 2004 Dec;136(6):1183-91 [15657574.001]
  • [Cites] Thyroid. 2008 Mar;18(3):309-15 [18341377.001]
  • [Cites] Ann Surg. 2009 Aug;250(2):305-10 [19638924.001]
  • [Cites] World J Surg. 2007 May;31(5):946-56 [17426901.001]
  • [Cites] Thyroid. 2009 May;19(5):487-94 [19348580.001]
  • [Cites] World J Surg. 2002 Jan;26(1):22-8 [11898029.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):52-8 [14758572.001]
  • [Cites] World J Surg. 2006 May;30(5):780-6 [16411013.001]
  • [Cites] World J Surg. 2007 May;31(5):895-904 [17347896.001]
  • [Cites] Adv Anat Pathol. 2006 Mar;13(2):69-75 [16670460.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Surgery. 2006 Jan;139(1):28-32 [16364714.001]
  • [Cites] Surgery. 2009 Feb;145(2):176-81 [19167972.001]
  • [Cites] N Engl J Med. 2003 Oct 16;349(16):1517-25 [14561794.001]
  • [Cites] World J Surg. 2001 Jun;25(6):723-7 [11376406.001]
  • [Cites] Chirurg. 2009 Feb;80(2):88-98 [19151959.001]
  • (PMID = 19902289.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


56. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M: Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol; 2009 Feb;16(2):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
  • Thyroid cells in peripheral circulation have been linked to thyroid cancer (TC).
  • Thirty-four patients underwent 20 +/- 14 months median follow-up for papillary (n = 31, 91%), follicular (n = 2) or Hurthle cell (n = 1) TC.
  • Advanced-stage disease occurred in 24% at presentation, and 11 (32%) developed cervical node metastases or recurrence requiring reoperation during follow-up.
  • [MeSH-major] RNA, Messenger / blood. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cell Differentiation. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroglobulin / genetics. Thyroglobulin / immunology. Thyroidectomy. Thyrotropin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015922.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


57. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid; 2006 Dec;16(12):1229-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
  • This analysis was performed to determine the effect of initial therapy on the outcomes of thyroid cancer patients.
  • Treatments employed included near-total thyroidectomy, administration of radioactive iodine, and thyroid hormone suppression therapy.
  • Near-total thyroidectomy, radioactive iodine, and aggressive thyroid hormone suppression therapy were each independently associated with longer overall survival in high-risk patients.
  • Near-total thyroidectomy followed by radioactive iodine therapy, and moderate thyroid hormone suppression therapy, both predicted improved overall survival in stage II patients.
  • No treatment modality, including lack of radioactive iodine, was associated with altered survival in stage I patients.
  • We also conclude that radioactive iodine therapy is beneficial for stage II, III, and IV patients.
  • Importantly, we show for the first time that superior outcomes are associated with aggressive thyroid hormone suppression therapy in high-risk patients, but are achieved with modest suppression in stage II patients.
  • We were unable to show any impact, positive or negative, of specific therapies in stage I patients.
  • [MeSH-major] Carcinoma, Papillary / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Follicular / therapy. Adult. Antithyroid Agents / therapeutic use. Cohort Studies. Female. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Registries. Risk. Survival Analysis. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2007 Jun;17(6):595-6; author reply 596-7 [17614785.001]
  • (PMID = 17199433.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16524
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antithyroid Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


58. Yasmeen S, Cress R, Romano PS, Xing G, Berger-Chen S, Danielsen B, Smith LH: Thyroid cancer in pregnancy. Int J Gynaecol Obstet; 2005 Oct;91(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer in pregnancy.
  • OBJECTIVE: To compare stage at diagnosis, treatment and survival among pregnant women with thyroid cancer to non-pregnant women with thyroid cancer, and to assess the impact of treatment on maternal and perinatal outcomes.
  • METHODS: A database containing maternal and newborn discharge records linked to the California Cancer Registry was queried to obtain information on all thyroid cancers from 1991-1999.
  • Women with thyroid cancer occurring during pregnancy were compared to age-matched non-pregnant women with thyroid cancer.
  • RESULTS: 595 cases of thyroid cancers were identified (129 antepartum and 466 postpartum).
  • About 64% of thyroid cancers were diagnosed at stage 2 among pregnant women versus 58% among non-pregnant controls.
  • The odds of thyroid cancer were 1.5 times higher among Asian/Pacific Islanders than among Non-Hispanic White women.
  • Pregnancy had no significant effect on mortality after diagnosis of thyroid cancer.
  • CONCLUSIONS: Thyroid cancer discovered during or after pregnancy does not appear to have a significant impact on the prognosis of the disease.
  • [MeSH-minor] Adenocarcinoma, Follicular / mortality. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / therapy. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / therapy. Adult. Female. Humans. Pregnancy. Prognosis. Retrospective Studies. Survival Analysis


59. Enomoto K, Sakurai K, Amano S, Shiono M: [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2490-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast carcinoma with local hemorrhage during a control of hyperthyroidism].
  • A medical check-up was done and diagnosed as T4b, N0, M0, stage IIIB of the breast cancer by a close inspection.
  • We waited for a thyroid function to be normalized.
  • In January 2009, we observed a bleeding from the part of the breast cancer.
  • We controlled the thyroid function by internal medicine.
  • Because we were able to control the hyperthyroidism this time and a thyroid function to be stabilized for a local advanced breast carcinoma with the hemorrhage temporarily, and were able to operate for the breast cancer, as we reported it in this study.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Ductal, Breast / complications. Hemorrhage / etiology. Hyperthyroidism / drug therapy
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / surgery. Carcinoma, Papillary / complications. Carcinoma, Papillary / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037465.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Rumiantseva UV, Il'in AA, Rumiantseva PO, Medvedev VS, Abrosimov AIu, Zaletaev DV: [Familial well-differentiated thyroid carcinoma]. Vopr Onkol; 2006;52(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Familial well-differentiated thyroid carcinoma].
  • Medical Research Institute of Radiology, Russian Academy Forty-eight cases of familial disease (24 families) (4.3%) were identified among 1,118 patients with well-differentiated thyroid carcinoma who had been either examined or treated at the Clinic of Medical Research Institute of Radiology (1995-2004).
  • In 86% of the study group, papillary thyroid carcinoma (PTC) was associated with tumor of the identical histological pattern while the remaining families revealed association with follicular or medullary thyroid cancer.
  • Carcinoma inheritable from mother was the most frequent (75%).
  • No differences in manifestation, histological pattern, stage or clinical course were established following a detailed evaluation of clinico-morphological data on 43 familial and 172 sporadic (control) cases in both groups.
  • The analysis pointed to a significantly higher incidence of concomitant thyroid pathology in the familial thyroid cancer group.
  • [MeSH-major] Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adult. Aged. Alanine. Carcinoma, Medullary / genetics. Carcinoma, Papillary / genetics. Female. Glycine. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-ret / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715702.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


61. Kitahara S, Ito T, Hamatani S, Shibuya K, Shiba T: Thyroid papillary carcinoma recurring as squamous cell carcinoma: report of a case. Surg Today; 2006;36(2):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid papillary carcinoma recurring as squamous cell carcinoma: report of a case.
  • We report a case of local squamous cell carcinoma recurrence of thyroid papillary carcinoma, 4 years after subtotal thyroidectomy, in an 82-year-old woman.
  • The papillary cancer of the right thyroid was histopathologically classified as T2a, N0, M0, Ex1; pT2a, pN1b, pEx1; Stage III.
  • The tumor was judged cytologically to be class III, defined as a suspicious malignancy and, after reoperation, it was diagnosed histopathologically as papillary carcinoma recurrence with extensive squamous metaplasia.
  • The recurrent papillary carcinoma was thought to have changed to a squamous cell carcinoma because most of the tumor was occupied by atypical squamous cells, with a small amount of glandular tissue.
  • The primary tumor was histologically diagnosed as a well-differentiated papillary carcinoma at the initial operation.
  • It contained numerous tall neoplastic cells with eosinophilic granules and pseudostratified nuclei, indicating that it could potentially transform into squamous cell carcinoma.
  • We report this case as an example of how squamous cell carcinoma of the thyroid can develop.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Thyroid Neoplasms / pathology. Thyroidectomy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jul;13(7):742-6 [10912933.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):77-80 [3940424.001]
  • [Cites] Jpn J Surg. 1990 May;20(3):341-5 [2193180.001]
  • [Cites] Endocrinol Metab Clin North Am. 1996 Mar;25(1):49-68 [8907680.001]
  • [Cites] Cleve Clin Q. 1976 WINTER;43(4):207-15 [1000814.001]
  • [Cites] Surg Today. 1999;29(3):204-8 [10192728.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] Am J Surg Pathol. 1978 Jun;2(2):133-40 [655339.001]
  • [Cites] Am Surg. 1974 May;40(5):290-4 [4821352.001]
  • [Cites] J Surg Oncol. 1982 Jan;19(1):36-43 [7057643.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Am J Surg. 1988 Jul;156(1):44-6 [3394892.001]
  • [Cites] Arch Surg. 1967 Feb;94(2):235-9 [6016271.001]
  • [Cites] World J Surg. 1985 Feb;9(1):128-35 [3984364.001]
  • [Cites] Thyroid. 2003 Apr;13(4):371-80 [12812214.001]
  • [Cites] Am J Surg. 1968 Jul;116(1):125-9 [5652346.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2080-3 [7296515.001]
  • (PMID = 16440166.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Tachihara-Yoshikawa M, Ishida T, Watanabe K, Sugawara A, Kanazawa K, Kanno R, Suzuki T, Niimi T, Kimura S, Munakata M: Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas. Fukushima J Med Sci; 2008 Dec;54(2):61-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretoglobin (SCGB) 3A2 is a downstream target gene for the thyroid transcription factor-1 (TITF1).
  • The expression in papillary adenocarcinomas was seen at higher frequency than that in tubular adenocarcinomas.
  • There was no significant relationship between SCGB3A2 expression and tumor differentiation, and pathological stage.
  • [MeSH-major] Adenocarcinoma / chemistry. Carcinoma, Small Cell / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2006 May 1;173(9):958-64 [16456148.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54358-68 [15485815.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):318-24 [10102618.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:193-201 [11193757.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:234-48 [11193760.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:249-67 [11193761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):2021-36 [11682631.001]
  • [Cites] Am J Hum Genet. 2002 Mar;70(3):718-25 [11813133.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9 [12051626.001]
  • [Cites] Mech Dev. 2002 Jun;114(1-2):201-4 [12175512.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1058-67 [12379752.001]
  • [Cites] Cytogenet Genome Res. 2002;97(1-2):120-7 [12438750.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Dec 1;166(11):1498-509 [12406855.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):924-30 [12847263.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Aug;131(4):291-5 [12915772.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5671-81 [8065304.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6531-6 [7896788.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2056-64 [8628271.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6881-8 [8636114.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):445-52 [8729987.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):30-2 [9059352.001]
  • [Cites] Cell Growth Differ. 1998 Jun;9(6):475-85 [9663466.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):227-31 [10066094.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Dec;287(6):L1193-8 [15531759.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9659-69 [16266985.001]
  • [Cites] Immunol Lett. 2005 Feb 15;97(1):123-9 [15626484.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1673-6 [16980598.001]
  • (PMID = 19418968.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010449-06; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / SCGB3A2 protein, human; 0 / Secretoglobins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9060-09-7 / Uteroglobin
  • [Other-IDs] NLM/ NIHMS102164; NLM/ PMC2743607
  •  go-up   go-down


63. Varandas VM, Coelho SM, Soeiro AP, Coeli CM, Carvalho DP, Buescu A, Vaisman M: [Clinical repercussion of the 6th edition TNM staging system classification on differentiated thyroid carcinoma]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):825-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical repercussion of the 6th edition TNM staging system classification on differentiated thyroid carcinoma].
  • The TNM classification of UICC is used for predicting the outcome of thyroid cancer.
  • Sixty-nine patients had papillary carcinoma, 14 follicular, 4 Hürthle cell, and 3 mixed.
  • For the stage IV there was a significant change in remission, however there was no difference comparing IV and IV C.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891247.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down






Advertisement